Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLA-Match Tolerance
NCT03707262Phase 2Recruiting
- Start
- Nov 2019
- Primary completion
- May 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Donor CD34+ and CD3+ cells in kidney transplant rejection. Started Nov 2019; status: recruiting.
02
Drugs
Donor CD34+ and CD3+ cells
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03707262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707262.